Ilaris
Novartis targets specific patient population with strong Ilaris Phase 3 data
November 14, 2017Manufacturing and Production, Research and Development Ilaris, Novartis, cardiovascular, heart attack, heart disease, pharma
Novartis has presented new Phase 3 data on its cardiovascular drug Ilaris (canakinumab) which demonstrate particular efficacy in a specific …
EU approval for Ilaris
March 4, 2013Sales and Marketing Ilaris, Novartis
Novartis’ Ilaris has become the first biologic approved by the European Commission to treat patients suffering acute gouty arthritis attacks …
FDA wants more information on Novartis arthritis drug
August 31, 2011Sales and Marketing FDA, Ilaris, Novarits, canakinumab
The FDA has asked Novartis for more information on its gouty arthritis drug canakinumab. The regulator’s request came in a …
FDA rejects Novartis’ Ilaris for gouty arthritis
June 22, 2011Research and Development Ilaris, Novartis, gouty arthritis
An FDA advisory panel has voted against backing Novartis’ Ilaris for gouty arthritis because of safety concerns. Ilaris (canakinumab) is …
NICE to appraise hep C drugs Victrelis and telaprevir
May 26, 2011Sales and Marketing Brinavess, Ilaris, NICE, Victrelis, Xarelto, Zytiga, telaprevir
NICE’s next round of drug appraisals is set to include two new hepatitis C drugs – Merck Sharpe and Dohme’s …
Novartis launches Ilaris in the UK
January 12, 2010Sales and Marketing Ilaris, Novartis, cryopyrin-associated periodic syndrome
Novartis has launched its new biologic Ilaris in the UK as a treatment for cryopyrin-associated periodic syndrome. The rare debilitating …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
